论文部分内容阅读
作者用α-2b干扰素治疗33例慢性输血后非甲非乙型肝炎(NANBPTH)患者,以血清丙氨酸转氨酶(s-ALAT)和肝活检观察疗效,并探讨疗效与抗-HCV存在的关系。 33例瑞典患者接受开放性随机对照研究。病前均有输血史,s-ALAT>1.05μkat/L 1年以上;经肝活检证实,血清HBsAg、抗-HIV、抗核抗体、平滑肌抗体、线粒体抗体均阴性。22/33(67％)例抗-HCV阳性(Ortho试剂,ELISA法)。随机以2:1分组,治疗组20例(男18例,女2例),平均年龄为54.6(21～75)岁,平均病程为
The authors treated 33 patients with non-A, non-B hepatitis B (NANBPTH) after chronic blood transfusion with α-2b interferon and observed the effect of serum alanine aminotransferase (s-ALAT) and liver biopsy, and explored the efficacy and anti-HCV relationship. Thirty-three Swedish patients underwent an open-label randomized controlled study. Pre-morbid blood transfusion, s-ALAT> 1.05μkat / L more than 1 year; confirmed by liver biopsy, serum HBsAg, anti-HIV, anti-nuclear antibodies, smooth muscle antibodies, mitochondrial antibodies were negative. 22/33 (67%) anti-HCV positive (Ortho’s reagent, ELISA). The patients in the treatment group were randomly divided into 2 groups: 20 patients (18 males and 2 females) with a mean age of 54.6 (21-75 years) and an average duration of